Tesamorelin

Mechanism

Tesamorelin is a modified version of natural growth hormone-releasing hormone (GHRH) that is specifically FDA-approved to reduce stubborn visceral belly fat. It works by stimulating the pituitary gland to release growth hormone, which then targets deep abdominal fat deposits that are metabolically dangerous. Beyond fat reduction, it also supports improved body composition, cognitive function, and cardiovascular risk markers.

Effects

## Metabolic/Adipose System [Tier 1 - Phase III Human Data, FDA-Approved] - Reduces visceral adipose tissue (VAT) by 15-18% over 26-52 weeks in Phase III trials - Visceral fat is the metabolically dangerous deep abdominal fat associated with cardiovascular disease, insulin resistance, and systemic inflammation - Trunk fat ratio (visceral-to-subcutaneous) improves, indicating preferential visceral mobilization - Triglyceride reductions of 15-25% through enhanced hepatic lipid export and adipose lipolysis - Does NOT significantly reduce subcutaneous fat — targeted visceral effect ## Endocrine/GH Axis [Tier 1 - Human Data] - Modified GHRH analog (trans-3-hexenoic acid at N-terminus) with enhanced enzymatic stability - Produces robust GH pulses and sustained IGF-1 elevation of 40-80% above baseline - Preserves pulsatile GH release and somatostatin feedback - IGF-1 elevation is higher than CJC-1295 no DAC or sermorelin at standard doses ## Hepatic System [Tier 1 - Human Data] - Reduces hepatic fat content (intrahepatic lipid) by 30-40% in patients with NAFLD - Improvements in liver enzymes (ALT, AST) correlated with hepatic fat reduction - EGRIFT trial in HIV lipodystrophy patients showed significant hepatic steatosis improvement ## Cardiovascular System [Tier 1 - Human Data] - Improvements in inflammatory markers: hs-CRP, IL-6 reductions correlate with visceral fat loss - Improved carotid intima-media thickness (cIMT) in 12-month studies — suggesting vascular remodeling benefit - Blood pressure improvements modest but consistent with visceral fat reduction ## Musculoskeletal System [Tier 2 - Secondary Endpoints] - Lean body mass tends to increase modestly (1-2 kg) as visceral fat decreases - IGF-1 elevation supports collagen synthesis and bone metabolism - Some patients report improved exercise performance secondary to body composition improvements ## Central Nervous System [Tier 1 - Human Data] - COGNITIVE studies in HIV patients showed improved executive function, verbal memory, and processing speed - GH/IGF-1 axis supports hippocampal neurogenesis and synaptic plasticity - Improved sleep quality consistent with other GH secretagogues - One of the few peptides with actual cognitive endpoint data in controlled trials ## Immune System [Tier 2 - HIV Population Data] - Visceral fat reduction in HIV patients reduces chronic immune activation associated with lipodystrophy - No adverse effect on CD4 counts or viral load in HIV patients on ART - May reduce cardiovascular risk specific to the HIV/ART population

Practitioner Guide

## Clinical Positioning Tesamorelin is unique: it is the ONLY GHRH analog with current FDA approval (Egrifta SV, for HIV-associated lipodystrophy). Its primary clinical niche is visceral fat reduction, where it has stronger evidence than any other peptide. Off-label use for non-HIV visceral adiposity is common in peptide clinics. ## FDA-Approved Indication - Egrifta SV: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy - 2mg daily SC injection - Available through specialty pharmacies with prior authorization ## Off-Label Use (Non-HIV Patients) - Visceral fat reduction in metabolic syndrome - NAFLD/NASH (hepatic fat reduction) - Cognitive optimization (based on HIV cognition trial data) - Anti-aging GH optimization (more potent than sermorelin or CJC-1295) ## Dosing ### FDA-Approved (HIV Lipodystrophy) - 2mg SC daily (abdomen), same time each day ### Off-Label Clinical Dosing - 1-2mg SC daily at bedtime, fasted - Some clinics use 1mg daily as a cost-effective alternative (still effective, slightly less VAT reduction) - Can be combined with ipamorelin (200mcg) for synergistic GH release, though this is more aggressive than standard practice ## Practical Considerations - Significantly more expensive than CJC-1295 no DAC or sermorelin due to higher dose requirement and brand pricing - Reconstitution: Egrifta SV comes as a pre-mixed solution; compounded tesamorelin requires standard reconstitution - Injection volume is larger than typical peptide injections (0.5-1mL vs. 0.1-0.3mL for most peptides) ## When to Choose Tesamorelin Over CJC-1295 no DAC - Patient has significant visceral adiposity (waist >40 inches male / >35 inches female) - Patient has NAFLD/NASH and wants GH-pathway approach - Patient has HIV lipodystrophy (FDA indication) - Patient wants cognitive optimization AND body composition improvement - Patient wants the peptide with the most regulatory validation ## When CJC-1295 no DAC Is Preferred - Cost is a factor (CJC is much cheaper) - General anti-aging/optimization without specific visceral fat concern - Patient is already lean and wants GH optimization for recovery/sleep - Stacking flexibility (CJC + IPA is simpler than tesamorelin + IPA) ## Blood Work Same as other GH peptides: IGF-1 baseline and monitoring. Tesamorelin tends to elevate IGF-1 more aggressively — monitor closely. - Add liver enzymes (ALT, AST) and lipid panel for visceral fat/NAFLD indication - CT or DEXA for visceral fat quantification if available (MRI is gold standard but expensive) ## Side Effects - Injection site reactions (erythema, pruritus): more common than with other GH peptides (up to 10%) - Arthralgia (joint pain): ~5%, reflects higher IGF-1 elevation — dose reduction resolves - Peripheral edema: ~5%, fluid retention from GH axis activation - Paresthesias: ~5%, carpal tunnel symptoms from IGF-1 elevation - Hypersensitivity reactions: rare but possible (includes the trans-3-hexenoic acid modification)

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  GHRH analogue stimulates GH release and elevates IGF-1 levels. IGF-1 promotes cell proliferation and may accelerate tumor growth. Tesamorelin prescribing information explicitly contraindicates use with active malignancy.
  Action: Do not use in patients with any active cancer diagnosis. This is a labeled contraindication.
• hard stop — Pregnancy
  Tesamorelin is contraindicated in pregnancy per prescribing information. Animal studies showed adverse developmental effects.
  Action: Do not use during pregnancy. This is a labeled contraindication. Discontinue immediately if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established during lactation.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis peptides are not designed for unsupervised pediatric use. Insufficient safety data in minors.
  Action: Do not provide peptide protocols to individuals under 18.
• requires physician — Diabetes
  Tesamorelin-induced GH elevation antagonizes insulin action. Clinical trials demonstrated increased blood glucose and HbA1c in diabetic patients.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory. Diabetes medication adjustment likely needed. HbA1c monitoring every 3 months.

Stacks featuring this peptide

Research Summary

## Tier 1 — Phase III/FDA-Approved Human Data - Phase III ACHIEVE trials: tesamorelin 2mg daily reduced VAT by 15-18% over 26 weeks (CT-measured) in HIV lipodystrophy - Extension studies: VAT reduction maintained over 52 weeks of continued treatment; VAT returned toward baseline after discontinuation - Triglyceride reductions of 50-100 mg/dL in hypertriglyceridemic patients - EGRIFT trial: hepatic steatosis improvement measured by liver spectroscopy - COGNITIVE studies: improved executive function and verbal memory scores on standardized neuropsychological testing - Safety: well-tolerated over 2+ years of continuous use in HIV population; IGF-1 elevation rarely exceeded 3x ULN ## Tier 2 — Mechanistic/Secondary Human Data - IGF-1 elevation of 40-80% in most patients, with dose-dependent response - Visceral fat reduction is preferential (not proportional to total fat loss), suggesting specific lipolytic pathway activation in visceral adipocytes - Improved carotid IMT measurements suggest cardiovascular structural benefit beyond weight/fat changes - Lean mass preservation/increase of 1-2 kg over treatment period ## Tier 3 — Preclinical - Trans-3-hexenoic acid modification confers 10x enzymatic stability vs. native GHRH - Full GHRH receptor agonist with equivalent maximal efficacy to native GHRH(1-44) - Rodent models confirm preferential visceral fat mobilization mechanism involves upregulated HSL and ATGL expression in visceral vs. subcutaneous adipocytes ## Evidence Gaps - Non-HIV population data limited to small studies and clinic observations - Long-term cancer safety in non-HIV populations not studied - Optimal dose for non-HIV use not established - Comparison with CJC-1295 no DAC or sermorelin never conducted - Effects on cognitive function in non-HIV aging population not studied in RCTs